论文部分内容阅读
目的检测妊娠期高血压疾病患者及其胎儿脐血血清中血小板活化因子(PAF)的水平,以探讨PAF在妊娠期高血压疾病发病及胎儿生长发育中的作用。方法采用酶联免疫吸附技术(ELISA)测定150例妊娠期高血压疾病患者及50例正常妊娠妇女及其胎儿脐血血清中PAF水平。结果妊娠期高血压疾病患者血清中PAF浓度为(妊娠期高血压组为12.47±1.44μg/l,轻度子痫前期组为14.78±0.76μg/l,重度子痫前期组为17.39±1.46μg/l),明显高于对照组(9.43±0.73μg/l),比较差异有极显著性。妊娠期高血压疾病新生儿脐血血清中PAF水平(妊娠期高血压组为4.19±0.38μg/l,轻度子痫前期组为6.38±0.33μg/l,重度子痫前期组为8.44±0.41μg/l),对照组为(2.46±0.27μg/l)比较差异有极显著性。结论孕妇血清中PAF水平与妊娠期高血压疾病的发病及病情轻重有关,随着病情加重,PAF逐渐升高。脐血血清中PAF水平影响着胎儿及胎盘的生长发育。
Objective To detect the levels of platelet-activating factor (PAF) in patients with hypertensive disorder complicating pregnancy and fetal umbilical cord blood in order to explore the role of PAF in the pathogenesis of pregnancy-induced hypertension and fetal growth and development. Methods The serum levels of PAF in 150 cases of hypertensive disorder complicating pregnancy and 50 normal pregnant women and their umbilical cord blood were measured by enzyme-linked immunosorbent assay (ELISA). Results The serum levels of PAF in patients with gestational hypertension were 12.47 ± 1.44μg / l in gestational hypertension group, 14.78 ± 0.76μg / l in mild preeclampsia group and 17.39 ± 1.46μg in severe preeclampsia group / l) was significantly higher than the control group (9.43 ± 0.73μg / l), the difference was significant. PAF levels in umbilical blood serum of neonates with gestational hypertension (4.19 ± 0.38μg / l in gestational hypertension group, 6.38 ± 0.33μg / l in mild preeclampsia group and 8.44 ± 0.41 in severe preeclampsia group) μg / l), the control group (2.46 ± 0.27μg / l) compared with the difference was significant. Conclusions The serum levels of PAF in pregnant women are related to the severity of the disease and the incidence of hypertensive disorder complicating pregnancy. As the disease progresses, PAF gradually increases. PAF levels in cord blood serum affect fetal and placental growth and development.